189 related articles for article (PubMed ID: 30254074)
1. Structures of human cytochrome P450 1A1 with bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands.
Bart AG; Scott EE
J Biol Chem; 2018 Dec; 293(50):19201-19210. PubMed ID: 30254074
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 1A1 opens up to new substrates.
Munro AW
J Biol Chem; 2018 Dec; 293(50):19211-19212. PubMed ID: 30552114
[TBL] [Abstract][Full Text] [Related]
3. Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate.
Bart AG; Takahashi RH; Wang X; Scott EE
Drug Metab Dispos; 2020 Feb; 48(2):86-92. PubMed ID: 31757797
[TBL] [Abstract][Full Text] [Related]
4. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism.
Walsh AA; Szklarz GD; Scott EE
J Biol Chem; 2013 May; 288(18):12932-43. PubMed ID: 23508959
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling of cytochrome P450 1A1: enzyme-substrate interactions and substrate binding affinities.
Szklarz GD; Paulsen MD
J Biomol Struct Dyn; 2002 Oct; 20(2):155-62. PubMed ID: 12354067
[TBL] [Abstract][Full Text] [Related]
6. The Grapefruit Effect: Interaction between Cytochrome P450 and Coumarin Food Components, Bergamottin, Fraxidin and Osthole. X-ray Crystal Structure and DFT Studies.
Rossi M; Aktar S; Davis M; Hefter Feuss E; Roman-Holba S; Wen K; Gahn C; Caruso F
Molecules; 2020 Jul; 25(14):. PubMed ID: 32664320
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human and rat CYP1A1 enzyme by grapefruit juice compounds.
Santes-Palacios R; Romo-Mancillas A; Camacho-Carranza R; Espinosa-Aguirre JJ
Toxicol Lett; 2016 Sep; 258():267-275. PubMed ID: 27444380
[TBL] [Abstract][Full Text] [Related]
8. Natural furocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes.
Baumgart A; Schmidt M; Schmitz HJ; Schrenk D
Biochem Pharmacol; 2005 Feb; 69(4):657-67. PubMed ID: 15670584
[TBL] [Abstract][Full Text] [Related]
9. 7-Ethynylcoumarins: selective inhibitors of human cytochrome P450s 1A1 and 1A2.
Liu J; Nguyen TT; Dupart PS; Sridhar J; Zhang X; Zhu N; Stevens CL; Foroozesh M
Chem Res Toxicol; 2012 May; 25(5):1047-57. PubMed ID: 22443586
[TBL] [Abstract][Full Text] [Related]
10. Characterization of differences in substrate specificity among CYP1A1, CYP1A2 and CYP1B1: an integrated approach employing molecular docking and molecular dynamics simulations.
Kesharwani SS; Nandekar PP; Pragyan P; Rathod V; Sangamwar AT
J Mol Recognit; 2016 Aug; 29(8):370-90. PubMed ID: 26916064
[TBL] [Abstract][Full Text] [Related]
11. Exploring CYP1A1 as anticancer target: homology modeling and in silico inhibitor design.
Sangamwar AT; Labhsetwar LB; Kuberkar SV
J Mol Model; 2008 Nov; 14(11):1101-9. PubMed ID: 18665399
[TBL] [Abstract][Full Text] [Related]
12. Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally occurring furanocoumarins on skin tumor initiation.
Kleiner HE; Vulimiri SV; Reed MJ; Uberecken A; DiGiovanni J
Chem Res Toxicol; 2002 Feb; 15(2):226-35. PubMed ID: 11849049
[TBL] [Abstract][Full Text] [Related]
13. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin Agents.
Bart AG; Morais G; Vangala VR; Loadman PM; Pors K; Scott EE
Drug Metab Dispos; 2022 Jan; 50(1):49-57. PubMed ID: 34607808
[TBL] [Abstract][Full Text] [Related]
15. Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date.
Sridhar J; Goyal N; Liu J; Foroozesh M
Molecules; 2017 Jul; 22(7):. PubMed ID: 28698457
[TBL] [Abstract][Full Text] [Related]
16. Activation of microsomal glutathione S-transferase and inhibition of cytochrome P450 1A1 activity as a model system for detecting protein alkylation by thiourea-containing compounds in rat liver microsomes.
Onderwater RC; Commandeur JN; Menge WM; Vermeulen NP
Chem Res Toxicol; 1999 May; 12(5):396-402. PubMed ID: 10328749
[TBL] [Abstract][Full Text] [Related]
17. Ortho-Methylarylamines as Time-Dependent Inhibitors of Cytochrome P450 1A1 Enzyme.
Sridhar J; Liu J; Komati R; Schroeder R; Jiang Q; Tram P; Riley K; Foroozesh M
Drug Metab Lett; 2017; 10(4):270-277. PubMed ID: 28000546
[TBL] [Abstract][Full Text] [Related]
18. Modulation of CYP1A1 metabolism: From adverse health effects to chemoprevention and therapeutic options.
Mescher M; Haarmann-Stemmann T
Pharmacol Ther; 2018 Jul; 187():71-87. PubMed ID: 29458109
[TBL] [Abstract][Full Text] [Related]
19. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids.
Androutsopoulos VP; Papakyriakou A; Vourloumis D; Spandidos DA
Bioorg Med Chem; 2011 May; 19(9):2842-9. PubMed ID: 21482471
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: role of pentylresorcinol moiety.
Yamaori S; Okushima Y; Masuda K; Kushihara M; Katsu T; Narimatsu S; Yamamoto I; Watanabe K
Biol Pharm Bull; 2013; 36(7):1197-203. PubMed ID: 23811569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
